Setback For Athenex, Hanmi As CRL Requests New Trial

Another US Delay For Korean Firm's Assets

Hanmi partner Athenex has had a US complete response letter for its oral paclitaxel plus encequidar product for the treatment of metastatic breast cancer, amid concerns of safety risks associated with an increase in neutropenia-related sequelae. While the decision marks another setback for Hanmi in the US, Athenex is aiming to resolve the issues.

Doctor with Mammography - Image
Should Conduct New Adequate Clinical Trial • Source: Shutterstock

The US Food and Drug Administration's (FDA) issuance of a complete response letter (CRL) on Athenex, Inc.’s new drug application for its oral paclitaxel plus encequidar product for metastatic breast cancer is disappointing, not only for the US firm but also its licensor, South Korea's Hanmi Pharmaceutical Co., Ltd., which will see an approval delay for another of its product candidates. 

In the CRL decision, the FDA indicated its concern of a safety risk to patients in terms of an increase...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category